标题
Atezolizumab for the treatment of triple-negative breast cancer
作者
关键词
-
出版物
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 28, Issue 1, Pages 1-5
出版商
Informa UK Limited
发表日期
2018-11-26
DOI
10.1080/13543784.2019.1552255
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
- (2018) Carsten Denkert et al. LANCET ONCOLOGY
- Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
- (2018) Andrew Tutt et al. NATURE MEDICINE
- A Comprehensive Immunologic Portrait of Triple-Negative Breast Cancer
- (2018) Zhixian Liu et al. Translational Oncology
- Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
- (2018) Jennifer K. Litton et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer
- (2018) Leisha A. Emens et al. JAMA Oncology
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- (2018) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up
- (2018) Sylvia Adams et al. JAMA Oncology
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
- (2017) Mark Robson et al. NEW ENGLAND JOURNAL OF MEDICINE
- FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum‐Containing Chemotherapy
- (2017) Yang‐Min Ning et al. ONCOLOGIST
- Integrated analysis of somatic mutations and immune microenvironment of multiple regions in breast cancers
- (2017) Taigo Kato et al. Oncotarget
- Association Between Genomic Metrics and Immune Infiltration in Triple-Negative Breast Cancer
- (2017) Thomas Karn et al. JAMA Oncology
- Do platinum salts fit all triple negative breast cancers?
- (2016) L. Gerratana et al. CANCER TREATMENT REVIEWS
- Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
- (2016) Rita Nanda et al. JOURNAL OF CLINICAL ONCOLOGY
- Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor
- (2016) Rong Deng et al. mAbs
- nab-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors
- (2016) Hatem Soliman OncoTargets and Therapy
- A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors
- (2016) Samit Chatterjee et al. Oncotarget
- Clinical significance of tumor-infiltrating lymphocytes in breast cancer
- (2016) Sasha E. Stanton et al. Journal for ImmunoTherapy of Cancer
- Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers
- (2015) Carsten Denkert et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune Checkpoint Blockade in Cancer Therapy
- (2015) Michael A. Postow et al. JOURNAL OF CLINICAL ONCOLOGY
- Releasing the Brakes on Cancer Immunotherapy
- (2015) Antoni Ribas NEW ENGLAND JOURNAL OF MEDICINE
- Neoantigens in cancer immunotherapy
- (2015) T. N. Schumacher et al. SCIENCE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Somatic mutation load of estrogen receptor-positive breast tumors predicts overall survival: an analysis of genome sequence data
- (2014) Svasti Haricharan et al. BREAST CANCER RESEARCH AND TREATMENT
- The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis
- (2014) Ezzeldin M. Ibrahim et al. BREAST CANCER RESEARCH AND TREATMENT
- Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199
- (2014) Sylvia Adams et al. JOURNAL OF CLINICAL ONCOLOGY
- Measures of Outcome in Metastatic Breast Cancer: Insights From a Real-World Scenario
- (2014) M. Bonotto et al. ONCOLOGIST
- Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98
- (2013) Sherene Loi et al. JOURNAL OF CLINICAL ONCOLOGY
- Mutational heterogeneity in cancer and the search for new cancer-associated genes
- (2013) Michael S. Lawrence et al. NATURE
- Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents
- (2012) F. Andre et al. ANNALS OF ONCOLOGY
- Dissecting the Heterogeneity of Triple-Negative Breast Cancer
- (2012) Otto Metzger-Filho et al. JOURNAL OF CLINICAL ONCOLOGY
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
- (2011) Brian D. Lehmann et al. JOURNAL OF CLINICAL INVESTIGATION
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now